Algernon Pharmaceuticals: Investigating a Novel Therapy for Stroke Patients Using the Psychedelic Drug N,N-Dimethyltryptamine (DMT)

Stock Information for Algernon Pharmaceuticals

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Algernon Pharmaceuticals

Algernon Announces $1M Private Placement
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
Algernon Announces Warrant Extension
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.